BRCA1 and BRCA2 Mutations in an Asian Clinic-based Population Detected Using a Comprehensive Strategy
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 16 (11), 2276-2284
- https://doi.org/10.1158/1055-9965.epi-07-0403
Abstract
Background and objective: Genetic testing for germ line mutations in the BRCA1 and BRCA2 genes for some families at high risk for breast and/or ovarian cancer may yield negative results due to unidentified mutations or mutations with unknown clinical significance. We aimed to accurately determine the prevalence of mutations in these genes in an Asian clinic-based population by using a comprehensive testing strategy. Materials and Methods: Ninety-four subjects from 90 families were accrued from risk assessment clinics. In addition to conventional mutational screening of BRCA1 and BRCA2, multiplex ligation-dependent probe amplification for the detection of large genomic rearrangements, evaluation of splice site alterations using transcript analysis and SpliceSiteFinder prediction, and analysis of missense mutations of unknown significance by multiple sequence alignment, PolyPhen analysis, and comparison of Protein Data Bank structures were incorporated into our testing strategy. Results: The prevalence rates for clearly deleterious BRCA1 and BRCA2 mutations were 6.7% (6 of 90) and 8.9% (8 of 90), respectively, or 7.8% (7 of 90) and 11.1% (10 of 90), respectively, by including missense mutations predicted to be deleterious by computational analysis. In contrast to observations from European and American populations, deleterious mutations in BRCA2 (10 families) were more common than for BRCA1 (7 families). Overall, the frequency of mutations was 12.2% (n = 11) by conventional screening. However, by including deleterious mutations detected using multiplex ligation-dependent probe amplification (n = 1), transcript analysis (n = 2), and computational evaluation of missense mutations (n = 3), the frequency increased substantially to 18.9%. This suggests that the comprehensive strategy used is effective for identifying deleterious mutations in Asian individuals at high risk for breast and/or ovarian cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2276–84)Keywords
This publication has 47 references indexed in Scilit:
- Intronic alterations inBRCA1andBRCA2: effect on mRNA splicing fidelity and expressionHuman Mutation, 2006
- Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast CancerJAMA, 2006
- Characterization ofBRCA1andBRCA2Mutations in a Large United States SampleJournal of Clinical Oncology, 2006
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2American Journal of Human Genetics, 2004
- BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancerJournal of Medical Genetics, 2003
- RNA analysis of eightBRCA1andBRCA2unclassified variants identified in breast/ovarian cancer families from SpainHuman Mutation, 2003
- Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2Genes, Chromosomes and Cancer, 2003
- BRCA1 and BRCA2 in Indian breast cancer patientsHuman Mutation, 2002
- BRCA1 andBRCA2 sequence variants in Chinese breast cancer familiesHuman Mutation, 2002
- Sequence and structure-based prediction of eukaryotic protein phosphorylation sitesJournal of Molecular Biology, 1999